Downloading...
Download

SENS

"Sens Stock: Eyeing 1000% Return Potential"Sens Stock: Eyeing 38 Cents for All-Time Low Buy Opportunity Sens stock, a compelling asset in the realm of healthcare technology, is catching the attention of investors as it approaches the 38-cent mark, representing all-time lows. With the formation of a double bottom and falling wedge pattern, this potential buy opportunity could pave the way for a remarkable turnaround, offering the potential for a 1000% return to previous highs. Let's explore what Sens stock represents and delve into the promising prospects it holds. Understanding Sens Stock Sens is a healthcare technology company focused on developing innovative solutions to improve patient care and outcomes. With a portfolio that includes wearable devices, remote monitoring systems, and data analytics platforms, Sens is at the forefront of revolutionizing healthcare delivery and management. Through its cutting-edge technologies, Sens aims to empower patients, healthcare providers, and caregivers alike to make more informed decisions and enhance the quality of care. The 38-Cent Buy Opportunity As Sens stock approaches the 38-cent mark, it presents a compelling opportunity for investors to initiate positions at all-time lows. The formation of a double bottom pattern, coupled with a falling wedge, adds further conviction to this potential buy opportunity. By strategically entering the market at this critical juncture, investors may position themselves for substantial gains as the stock seeks to reverse its downtrend and embark on a new bullish trajectory. Potential for a 1000% Return The buy opportunity at 38 cents holds significant upside potential for investors eyeing a potential return to previous highs. With the formation of a double bottom and falling wedge pattern signaling a potential trend reversal, Sens stock could experience a dramatic turnaround, offering the potential for a 1000% return to previous highs. This remarkable upside underscores the attractive risk-reward profile of the investment opportunity presented by Sens stock at current levels. Conclusion: Navigating the Path Forward In conclusion, Sens stock presents a compelling buy opportunity at 38 cents, representing all-time lows and supported by the formation of a double bottom and falling wedge pattern. As investors eye the potential for a 1000% return to previous highs, prudent risk management strategies are essential to navigate the inherent volatility of the market. By carefully assessing the fundamental strengths of Sens as a healthcare technology company and monitoring technical indicators for signs of a bullish reversal, investors can position themselves strategically to capitalize on the promising prospects offered by Sens stock in the journey ahead.
AMEX:SENS
by UnknownUnicorn2319099
Senseonics Reversing. SENSEither a Wave 4 WXY pattern or a more general turnaround. Both scenarios are bearish. Note divergences and dropping momentum also. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets going down are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
AMEX:SENSShort
by Rykin_Capital
1
SENS Continues Holding LevelsPulled SENS back up again after a few weeks and see that it's still holding the same fib and trendline levels as it was when we first drew out the fib retracement. It's also now holding the 50DMA consistently as it steadily rises. For some context, this company develops and commercializes continuous glucose monitoring systems for diabetes patients. Senseonics offers the Eversense and Eversense XL products in its lineup. These are implantable CGM systems for measuring glucose levels with an under-skin sensor, and a removable and rechargeable smart transmitter. Sensonics also offers an app for real-time diabetes metrics monitoring. Other Highlights: - HC Wainwright $6 target and buy rating last month - Collab with University Hospitals Accountable Care Organization - Raised $50 million in gross proceeds through completion of At-the-Market equity offering program last quarter. Proceeds earmarked "primarily for debt service" -Year-To-Date up over 320% so far
AMEX:SENS
by PennyStocks101
SENS Back Testing The 382 Fib Watching To Act As SupportThe thing about SENS is that it's been a company crushing it in 2021. When it was first discussed this year it was still trading below $1. Despite recent volatility, it's up significantly year-to-date. I think volume remains steady but definitely on the lower end of the range. But good data from the last presentation on its PROMISE study seems to have sparked more attention. "The data evaluating the safety and accuracy of the next generation Eversense system was presented by Satish Garg , MD, Professor of Medicine at the Barbara Davis Center of the University of Colorado, Denver , and the PROMISE study group Principal Investigator (PI). The Company presented previously released information demonstrating performance matching that of the current 90-day sensor available in the United States , with reduced calibration, down to one per day, with duration extended to 180 days. Accuracy measurements discussed in the oral presentation include a mean absolute relative difference (MARD) of 9.1% for the primary sensor and confirmed hypoglycemia alert detection rates at 60 mg/dL of 87% and at 70 mg/dL of 93%. For the subset of 43 modified sensors (referred to as the SBA sensor), the MARD was 8.5% and the confirmed hypo alert detection rates at 60 mg/dL and 70 mg/dL were 90% and 94%, respectively." Another area of potential support/resistance is just below the 382 fib line (in yellow), which has held so far this week. It was resistance a few weeks back. With SENS failing almost right at the 236 Fib line, technical traders are liking monitoring these levels closely. Latest on SENS: Best Penny Stocks to Buy Right Now? 7 Small-Caps For Your Morning List
AMEX:SENS
by PennyStocks101
SENS - Coming back to its senses! 🙌-Shares of Senseonics (NYSEMKT:SENS) are on the march in Friday’s pre-market action stock after the medtech firm reported positive test results for its glucose-monitoring system. SENS stock was up more than 30% at 8:30 a.m. Eastern. -SENS stock closed Thursday at $2.05 a share after surging over the past six month. The shares used to trade deep in penny stock territory, below 50 cents through most of 2020. -Senseonics is focused on developing and commercializing long-term implantable continuous glucose monitoring systems, or CGMs, for patients with diabetes. It is novel in that it can be implanted and then provide data for up to six months. -Big move comes after the firm said study results for both a primary and secondary glucose sensor — or an SBA sensor — showed promising preliminary results. The study sought to evaluate Senseonics’ Eversense CGM System in patients with diabetes, testing them over a 180-day period. The study is the basis of the pre-market application submissions to the U.S. Food and Drug Administration and to European regulators for a CE mark, the company said.
AMEX:SENSLong
by caldooninvestment
16
SENS Elliot Wave analysisIt looks like wave 2 has completed for SENS. They had a conference today march 9th about some things that were already known to us, but they made some things more clear. Quick summary of this conference: - Accuracy of the current device is best in class with a MARD of 8.5% - Medicare National Coverage as of Jan 1, 2021: - Avg "Supply Cost" (I assume this is for the hardware and consumables) : $1571 - CPT Code 0446T (device insertion) $1,916 average payment - CPT Code 0448T (device removal and insertion) $1,926 average payment - Ascencia's commercial world wide investment in Senseonics product marketing is expected to be $30M-$80M per year over 5 years (this is where they got the $250M in the previous conference) and expect the US Ascencia personnel assigned to Senseonics to be in the 80-160 range. - Eversense is Ascencia's first CGM product and they have exclusive rights to the sales and distribution. Product Pipeline: 2021+ : Eversense 180 and iCGM/interoperability (integrate with insulin pumps) 2023 : Eversense 365, 1 calibration/week, optional FGM (flash glucose monitoring - no transmitter needed) 2024 : Freedom System, FGM, entire diabetes spectrum covered out to T2 non-insulin using patients. (credits for this summary to ww.reddit.com/r/senseonics/comments/m18cxq/sens_hc_wainwright_conference_takeaways/) I'm now looking for a 5 structure to the upside for a wave 3. Pricetarget for wave 3 is around $10. How long this will take I'm not sure.
AMEX:SENS
by Slippe
1
SENS Elliot Wave analysisSENS is a medical tech company focused on the design and development of glucose monitoring products designed to help people with diabetes. Pricetarget wave 2 correction: $3.00 Pricetarget wave 3: $12-24. The pricetarget of wave 3 will likely be driven by the US FDA approval coming march 2021. Hype will most likely drive the early stages of wave 3. Hopefully this hype will be backed up by fundamental growth of the company where it starts to make profits and scale in the market. If they don't get FDA approval this stock will most likely fall. High risk high reward play. ~slippe
AMEX:SENS
by Slippe
12
$SENS broke out of pennant pre marketHello dear padawans of the charts. It looks like SENS broke out of the pennant pre market. You can monitor the price from here for a re-test of the pennant resistance as support or for a drop back within the pennant. If the top of the pennant becomes support we could start rallying again after this brief accumulation within the pennant (the price could also continue moving up without any re-test). RSI looks healthy as well as MACD. I entered a swing trade position here. Safe trades! Show your love: If you get anything out of this TA, please hit the like button so other can find this analysis quicker. Follow for more: If you want the best entry/exits just follow me, you won't regret. Thanks a lot! ***The ideas shared here are my opinion, not financial advise to place trades. Please do your own research before buying/selling stocks***
AMEX:SENS
by Safe_Trades
13
$SENS Breaks Out After Putting In Multiple Bottom$SENS is finally breaking to the upside after putting in multiple bottoms at the $.80 to $.90 level. Yesterday, $SENS put out news that we believe will continue to push the stock higher. As always, trade with caution and use protective stops. Good luck to all! --Cigna coverage decision adds more than 17 million covered lives for Eversense CGM-- GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement. Cigna Corporation is a global health service company dedicated to improving the health, well-being, and peace of mind of those who they serve. Cigna has more than 17 million medical customers and offers a Medicare Advantage plan in 17 states and Washington DC. This most recent coverage decision – in addition to Aetna (AET), Humana, HCSC Blue Cross Blue Shield and other health insurance providers – adds to the growing list of payers enabling their members to benefit clinically from the long-term Eversense CGM System. “Cigna prides itself on providing choice and access to quality care through connected, personalized solutions that allow their members to harness actionable insights to drive better healthcare results. Now Cigna members will have the choice to use the only long-term implantable CGM system available to help them better manage their diabetes,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Eversense provides actionable glucose data for users – not only where they are right now, but the direction they are headed. With superior accuracy, longest sensor life, on-body vibratory alerts and remote monitoring capability, users can proactively manage their glucose levels by treating their diabetes before they get to dangerously high or low levels. This information in the hands of the users allows them to manage their diabetes and experience healthier outcomes through personalized information and technology.” The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure. Patients who are interested in getting started on Eversense can sign up at www.eversensediabetes.com Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348). About Eversense The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see eversensediabetes.com About Senseonics Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
AMEX:SENS
by OptionsGains